PE 22- 28 10mg

Description

A peptide with neuroprotective and neurotransmitter-tonic properties.

The action of PE-22-28 is based on blocking the potassium ion channels TREK-1. These channels are located in brain regions involved in emotions, memory and cognitive functions. Blocking TREK-1 contributes to the antidepressant properties of the peptide. In addition, PE-22-28 shows potential as a support in recovery from stroke and in the treatment of neurodegenerative diseases, such as Alzheimer’s disease. It also offers synergistic potential with P-21.

Why is PE-22-28 worthwhile?
Neuroprotective and antidepressant properties
Detectable antidepressant effect within a few days
No addictive effects or withdrawal symptoms
Strong stimulation of neurogenesis (growth of new neurons)
Improvement of cognitive functions after trauma or heart attack
Protection against neurodegenerative diseases
Antimicrobial benefits with a broad spectrum of action
Reduces inflammation
Supports the fight against auto-immune diseases
Inhibits cancer cell formation and triggers apoptosis
Rapid and unique effects

The effects of PE-22-28 occur faster than traditional antidepressants. Neurogenesis is stimulated within days, resulting in effective relief of depressive symptoms. Unlike regular antidepressants, PE-22-28 does not affect sleep or cause withdrawal symptoms.

Moreover, the peptide exhibits antimicrobial activity: it disrupts the interaction between microorganisms and cell membranes, leading to the control of fungi, bacteria and inflammation. This also makes PE-22-28 promising in the treatment of antibiotic-resistant infections.

Broader scope
Supports recovery in autoimmune diseases
Helps fight inflammation and infection
Clinically studied for antibiotic-resistant bacteria
Anticancer activity through inhibition of cell division and induction of apoptosis

PE-22-28 offers a versatile and innovative approach to neurological, infectious and immunological disorders.

Unlike traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), which often cause side effects such as gastrointestinal complaints, weight gain and cardiovascular disturbances, PE-22-28 does not appear to have these drawbacks.

It is important to note that current knowledge about PE-22-28 is based primarily on animal studies and limited clinical data. Although preliminary results are promising, further research is needed to fully understand the safety and efficacy of PE-22-28 in humans.